Precigen reports first quarter 2024 financial results and business updates

–   pivotal phase 2 study data of prgn-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 asco annual meeting as a late-breaking oral presentation on june 3 rd – –   company to host a conference call on june 3 rd following the prgn-2012 asco presentation to discuss in detail the pivotal study results and provide business updates – –   prgn-2012 rolling bla submission, under an accelerated approval pathway, is anticipated in the second half of 2024; commercial readiness activities underway for a potential launch in 2025 – –   two trial-in-progress presentations for prgn-2009 in combination with pembrolizumab for the treatment of recurrent/metastatic cervical cancer and oropharyngeal cancer to be presented at asco – –   company and the recurrent respiratory papillomatosis foundation to co-sponsor the inaugural rrp awareness day on june 11 th to raise awareness and bring together individuals living with rrp, caregivers, clinicians, and government officials – –   cash, cash equivalents, and short-term investments totaled $44.8 million as of march 31, 2024 – germantown, md. , may 14, 2024 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter 2024 financial results and business updates.
PGEN Ratings Summary
PGEN Quant Ranking